AbbVie/ABBV
$166.42
1.25%-
1D1W1MYTD1YMAX
About AbbVie
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care products, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers.
Ticker
ABBV
Sector
Healthcare
Trading on
NYSE
Industry
Biotechnology & Drugs
CEO
Richard Gonzalez
Employees
50,000
Headquarters
North chicago, United States
Website
www.abbvie.com
AbbVie Metrics
BasicAdvanced
$289B
Market cap
48.78
P/E ratio
$3.36
EPS
0.58
Beta
$5.99
Dividend rate
3.79%
Dividend yield
Price and volume
Market cap
$289B
Beta
0.583
52-week high
$182.89
52-week low
$130.96
Average daily volume
5.7M
Dividend rate
$5.99
Financial strength
Current ratio
0.936
Quick ratio
0.834
Long term debt to equity
796.865
Total debt to equity
924.204
Dividend payout ratio (TTM)
181.01%
Enterprise value to free cash flow
106.446
Interest coverage (TTM)
8.95%
Management effectiveness
Return on assets (TTM)
4.24%
Return on equity (TTM)
55.92%
Return on investment (TTM)
5.61%
Valuation
Price to earnings (TTM)
48.783
Price to revenue (TTM)
5.316
Price to book
36.119
Price to free cash flow (TTM)
25.73
Five year average dividend yield
3.98%
Dividend yield (TTM)
3.66%
Forward dividend yield
3.79%
Growth
Revenue change (TTM)
-4.12%
Earnings per share change (TTM)
-20.78%
3-year revenue growth
5.85%
3-year earnings per share growth
-0.06%
3-year dividend per share growth
7.84%
What the Analysts think about AbbVie
Analyst Ratings
Majority rating from 29 analysts.
Price Targets
Average projection from 24 analysts.
High $207.00
Low $161.00
$166.42
Current price
$182.41
Average price target
AbbVie Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$12B
-13.92%
Net income
$1.4B
66.55%
Profit margin
11.12%
93.73%
AbbVie Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$2.91
$2.95
$2.79
$2.31
-
Expected
$2.81
$2.86
$2.77
$2.23
$3.05
Surprise
3.69%
3.25%
0.84%
3.76%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for AbbVie stock?
AbbVie (ABBV) has a market cap of $294B as of May 20, 2024.
What is the P/E ratio for AbbVie stock?
The price to earnings (P/E) ratio for AbbVie (ABBV) stock is 49.57 as of May 20, 2024.
Does AbbVie stock pay dividends?
Yes, the AbbVie (ABBV) stock pays dividends to shareholders. As of May 20, 2024, the dividend rate is $5.99 and the yield is 3.73%. AbbVie has a payout ratio of 181.01% on a trailing twelve-month basis.
When is the next AbbVie dividend payment date?
The next AbbVie (ABBV) dividend payment date is unconfirmed.
What is the beta indicator for AbbVie?
AbbVie (ABBV) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
What is the AbbVie stock price target?
The target price for AbbVie (ABBV) stock is $183.11, which is 10.03% above the current price of $166.42. This is an average based on projections from 25 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell AbbVie stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.